FAQ on Clene (NASDAQ: CLNN) and Its Role in Neurodegenerative Disease Treatment

What is Clene Inc. and what does it specialize in?

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS, Parkinson’s disease, and multiple sclerosis.

What is CNM-Au8 and how does it work?

CNM-Au8 is Clene’s lead investigational therapy that targets the NAD+ pathway to improve cellular energy production and utilization, aiming to restore and protect neurological function by addressing mitochondrial dysfunction, a common pathway in neurodegenerative diseases.

What neurodegenerative diseases is Clene targeting with CNM-Au8?

Clene is targeting amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease with CNM-Au8, focusing on neuroprotection and promoting remyelination to potentially alter the course of these conditions.

What phase are the clinical trials for CNM-Au8 in?

Clene is gearing up for phase three clinical trials for both ALS and MS, following extensive earlier trials that have demonstrated a strong safety profile for CNM-Au8.

How safe is CNM-Au8 based on clinical trials?

With over 650 years of cumulative subject exposure, CNM-Au8 has shown a strong safety profile with no serious adverse events linked to the drug, according to Clene’s clinical trials.

Where is Clene Inc. based and where are its operations?

Clene Inc. is based in Salt Lake City, Utah, with research and development (R&D) and manufacturing operations located in Maryland.

How can I find more information about Clene and its research?

For more information about Clene and its research, you can visit their official website at www.Clene.com or check the latest news and updates relating to CLNN at https://ibn.fm/CLNN.

What makes Clene’s approach to treating neurodegenerative diseases innovative?

Clene’s approach is innovative due to its focus on targeting mitochondrial dysfunction and the NAD pathway with CNM-Au8, a first-in-class therapy aimed at improving cellular energy production and utilization for neuroprotection and remyelination, backed by strong intellectual property.